195940.KQ HK inno.N Corporation Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Source
06:00
Feb 23
Feb 23
815 Money Talk
Undervalued Korean pharma laggards offer catch-up.
Many Korean pharma/biotech names with decent earnings have lagged while high-flying obesity/platform stocks are extended. Investors seeking lower-position entries should focus on undervalued names such as SK Biopharm, HK inno.N, Daewoong Pharmaceutical, and Dongkuk Pharmaceutical. SK Biopharm was pressured by US tariff exposure but remains solid; Dongkuk trades in a long box with earnings growth through 2028 and a market cap under KRW 1tn.
195940.KQ
HK inno.N Corporation
Long
1ST
—
About 195940.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 195940.KQ (HK inno.N Corporation) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Past 7 days, before deduplication: 2 other directions. Latest voices: Lee Chang-dae.